NCT02354417View on ClinicalTrials.gov

A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

PHASE1TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

February 28, 2017

Conditions

Hematologic Malignancies

Interventions

BIOLOGICAL

Biological: ProHema-CB

Each subject will receive one administration of ProHema-CB unit transplant.

Trial Locations (2)

91010

City of Hope, Duarte

02115-5450

Boston Children's Hospital, Boston

Sponsors

Lead Sponsor

Fate Therapeutics

All Listed Sponsors

lead

Fate Therapeutics

INDUSTRY

NCT02354417 - A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter